Showing results (21-30 of 43) with videos related to

Sort By:
Pageof 5
Cancers|November 27, 2021
Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate CancerT Hedley Carr, Carrie Adelman, Alan Barnicle, et al.
Gynecologic Oncology|November 7, 2021
Concordance of BRCA mutation detection in tumor versus blood, and frequency of bi-allelic loss of BRCA in tumors from patients in the phase III SOLO2 trialDarren R Hodgson, Jessica S Brown, Simon P Dearden, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 31, 2022
Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfoundKim N Chi, Alan Barnicle, Caroline Sibilla, et al.
Genes, Chromosomes & Cancer|May 24, 2023
The landscape of BRCA1 and BRCA2 large rearrangements in an international cohort of over 20 000 ovarian tumors identified using next-generation sequencingMelanie A Jones, Kirsten M Timms, Shanell Hatcher, et al.
Cancer Research|May 17, 2008
Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphomaValeria R Fantin, Andrey Loboda, Cloud P Paweletz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2022
Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNANobuaki Matsubara, Johann de Bono, David Olmos, et al.
JCO Precision Oncology|May 11, 2026
Detection of Homologous Recombination Repair Gene Mutations by Tumor Tissue and Circulating Tumor DNA Testing in Prostate Cancer in the Phase III PROpel TrialAndrew J Armstrong, Fred Saad, Mototsugu Oya, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|May 18, 2022
Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS StudyMichael Benatar, Joanne Wuu, Peter M Andersen, et al.
Hematological Oncology|August 7, 2019
A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCLToby A Eyre, Catherine Hildyard, Angela Hamblin, et al.
Molecular Cancer Therapeutics|November 16, 2014
Inhibition of PI3Kβ signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxelUrs Hancox, Sabina Cosulich, Lyndsey Hanson, et al.
Pageof 5